Ajanta Pharma's Shares Rise 1% After USFDA Nod for Topiramate Capsules

31 Aug 2023 , 10:32 AM

Ajanta Pharma witnessed a 1 % surge in shares, reaching Rs 1,748.90 during early trade on August 31. The boost follows the company’s recent approval from the United States Food and Drug Administration (USFDA) for its Topiramate extended-release capsules. As of the time of writing, the stock is trading at Rs 1,725, reflecting a slight dip of 0.18 % from the previous day’s close. 

Ajanta Pharma secures final USFDA approval for Topiramate extended-release capsules across four versions: 25 mg, 50 mg, 100 mg, and 200 mg. This drug is a generic equivalent of Supernus Pharmaceuticals Inc.’s Trokendi XR.

In accordance with an agreement with the innovator, Ajanta Pharma gains the right to launch Topiramate on or before February 1, 2026, subject to specific conditions. Notably, Ajanta Pharma has obtained 50 final ANDA approvals, with 41 already commercialized.

The company also holds 2 tentative approvals, while 22 ANDAs await USFDA clearance. Ajanta Pharma specializes in pharmaceutical formulations, with a significant emphasis on the branded generic business. Their operations span across India, Asia, and Africa.

For feedback and suggestions, write to us at [e-mail]